GEN and FiercePharma Compile Lists of Top Selling Drugs for 2013


Earlier this month, Genetic Engineering & Biotechnology News released its list of the top 25 best-selling drugs worldwide for 2013.  GEN's list, which the journal released on March 3 (see "The Top 25 Best-Selling Drugs of 2013"), was based on sales or revenue reported by biopharma companies in press announcements, annual reports, investor materials, and conference calls during 2013.  For each drug on its list, GEN has provided 2012 and 2013 sales, percent change from 2012 to 2013, and Q4 2013 sales and percent change for both 2012 and 2013.  2013 sales for the top 25 drugs range from $3.005 billion to $10.659 billion.  GEN's top 25 rankings are shown below, with the additional designation of small molecule or biologic for each drug that made GEN's list.

Genetic Engineering & Biotechnology News Top 25 Best-Selling Drugs of 2013

GEN Top 25Genetic Engineering & Biotechnology News, "The Top 25 Best-Selling Drugs of 2013," March 3, 2014.

Earlier this week, FiercePharma released its own list of best-selling drugs for 2013 -- albeit a top 10 list (see "The 10 best-selling drugs of 2013").  To create its list, FiercePharma obtained sales figures from EvaluatePharma.  2013 sales for the top 10 drugs on FiercePharma's list range from $5.501 billion to $11.02 billion. FiercePharma's top 10 rankings are shown below.

FiercePharma Top 10 Best-Selling Drugs of 2013

Fierce Top 10
FiercePharma, "The 10 best-selling drugs of 2013," March 25, 2014.

For additional information regarding this topic, please see:

• "GEN Compiles List of Top Selling Drugs for 2012," March 12, 2013


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:


McDonnell Boehnen Hulbert & Berghoff LLP on:

Popular Topics
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.